Preclinical study by MD Anderson Cancer Center represents the first use of IL-21 NK cells in glioblastoma
NK cells expressing interleukin-21 show promising antitumor activity in glioblastoma cells
Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained anti-tumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo, according to new research published by The University of Texas MD Anderson Cancer Center.
The preclinical findings, published in Cancer Cell, represent the first evidence that engineering NK cells, a type of innate immune cell, to secrete IL-21 resulted in strong activity against glioblastoma, a cancer type in need of more effective treatment options.
“Our research uncovered a previously unknown mechanism that plays an important role in NK cell memory against glioblastoma, highlighting the potential of NK cells engineered to express IL-21 in treating this disease. The ability of these IL-21 engineered natural killer cells to recognize and kill glioblastoma stem cell-like cells offers a highly promising therapeutic approach,” – said Katy Rezvani, Professor of Stem Cell Transplantation and Cellular Therapy.
Glioblastoma is an aggressive brain cancer with limited therapeutic options. Current treatment options for glioblastoma include surgery, radiation therapy and chemotherapy, but these options offer limited efficacy and patients have a median survival of just 18 to 21 months. According to the National Brain Tumor Society, the five-year survival rate for patients with glioblastoma is only 6.9%, with an average estimated length of survival of only eight months.
As part of the innate immune system, NK cells have a natural ability to recognize and eliminate GSCs. Engineering these cells can boost their fitness and antitumor activity. IL-21 is an immune signaling protein, or cytokine, shown to promote better metabolic fitness in NK cells.
In this study, first author Mayra Shanley, Principal Research Scientist at MD Anderson, and her co-authors used multiple in vitro and in vivo models to treat GSCs with NK cells engineered to express either IL-21 or IL-15, another cytokine used to boost NK cell activity.
While both groups of engineered NK cells displayed strong activity against GSCs in vitro, the IL-21 NK cells exhibited a stronger metabolic fitness than those expressing IL-15. Previous research by MD Anderson researchers identified lost metabolic fitness as a key mechanism in tumor resistance.
In vivo, the IL-21 NK cells showed limited toxicity and excellent tumor control in murine models of patient-derived GSC, compared to high toxicity and ineffective tumor control with IL-15 NK cells, which became exhausted over time.
Researchers also identified the CCAAT/Enhancer-Binding Protein (C/EBP), particularly CEBPD, as a critical transcription factor that plays an important role in regulating the sustained anti-GSC cytotoxicity of IL-21 NK cells.
When CEBPD was deleted, the potency of IL-21 NK cells decreased, while overexpression of CEBPD in NK cells increased their long-term cytotoxicity, metabolic fitness and anti-GSC potency in vivo. This enhanced activity was linked to distinct transcriptional and epigenetic signatures compared to IL-15 NK cells.
Based on these findings, researchers at MD Anderson will begin investigating the clinical application of IL-21 engineered NK cells in patients with glioblastoma, with a trial anticipated to begin later this year.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health.
Other posts featuring MD Anderson Cancer Center.